Clinical Trials
6 trialsNCT06966700 2026-06-01
A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
Merck Sharp & Dohme LLC
Phase 3 Recruiting
NCT04624204 2026-05-26
MK 7339-013
Merck Sharp & Dohme LLC
Phase 3 Active not recruiting
NCT04380636 2026-05-15
MK-7339-012
Merck Sharp & Dohme LLC
Phase 3 Active not recruiting
NCT03740165 2026-05-04
KEYLYNK-001
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT04191135 2026-03-03
KEYLYNK-009
Merck Sharp & Dohme LLC
Phase 2 Completed
NCT03976323 2026-02-25
Study of Pembrolizumab With Maintenance Olaparib or Maintenance Pemetrexed in First-line (1L) Metastatic Nonsquamous Non-Small-Cell Lung Cancer (NSCLC) (MK-7339-006, KEYLYNK-006)
Merck Sharp & Dohme LLC
Phase 3 Completed